期刊文献+

PRA、PRB蛋白在子宫内膜间质肉瘤中的表达及意义 被引量:1

Progesterone Receptors A and B Expressions and Their Clinical Significance in Endometrial Stromal Sarcoma
下载PDF
导出
摘要 目的:研究子宫内膜间质肉瘤(endometrial stromal sarcoma,ESS)孕激素受体亚型的表达情况及其临床意义。方法:选取1997年1月-2006年9月间青岛大学医学院、青岛市第三人民医院收治的34例的子宫内膜间质肉瘤,石蜡病理切片,用免疫组化法测定孕激素受体亚型(PRA,PRB)的表达情况。结果:PRA在ESS中的阳性表达率为73.5%(25/34),其中在低度恶性子宫内膜间质肉瘤(LESS)中的阳性表达率为87.0%(20/23),显著高于在高度恶性子宫内膜间质肉瘤(HESS)中的阳性表达率45.5%(5/11)(P<0.05);强度表达亦有显著差异(P<0.01)。ESS中PRB阳性表达率为58.8%(20/34),其中在LESS中的阳性表达率为73.9%(17/23),显著高于在HESS中的阳性表达率27.2%(3/11)(P<0.05);强度表达亦有显著差异(P<0.01)。②两种亚型与ESS临床分期的关系:PRAⅠ期、Ⅱ期、Ⅲ/Ⅳ期的阳性表达率分别为94.4%、66.7%、40%,3者比较有显著差异(P<0.05);强度比较亦有显著差异(P<0.01);PRBⅠ期、Ⅱ期、Ⅲ/Ⅳ期的阳性表达率分别为83.3%、50.0%、20.0%,3者比较有显著差异(P<0.05);强度比较亦有显著差异(P<0.05)。③9例淋巴结PRA、PRB阳性表达率22.2%(2/9),分别于ESS中PRA阳性率73.5%(25/34),PRB阳性率58.8%(20/34)比较,有显著差异(P<0.05,P<0.05)。④PRA(+),PRB(+)者,无瘤存活与因瘤死亡比较,两者都存在显著差异(P<0.01)。结论:PRA、PRB的丢失与子宫内膜间质肉瘤的恶性程度增高有关;与子宫内膜间质肉瘤的侵袭和转移有关;PRA、PRB的减少可能与淋巴结转移有关;PRA(+)、PRB(+)者预后较好。 Objective:To study the progesterone receptors A and B expressions and their clinical significance in ESS, Methods: The expressions of progesterone receptors A and B were determined by immunohistochemical method in 34 cases of endometrial stromal sarcoma. Results: OThe positive rate of PRA in ESS was 73.5% (25/34). in which LESS had a significantly higher PRA expression rate(87. 0% ) compared with HESS (45.5%), (P〈0.05). The positive rate of PRB in ESS was 58.80/00 (20/ 34),in which LESS had a significantly higher PRB expression rate (73.9 % ) compared with HESS (27.2 % ), (P〈0.05). (2) The positive rate of PRA in Ⅰ , Ⅱ and Ⅲ/Ⅳ: were 94.4%, and 40%, respectively with significant difference(P〈0.05) ; The positive rate of PRB in Ⅰ was 83. 3%, Ⅱ was 50. 0%, Ⅲ/Ⅳ was 20. 0%, they were demonstrated significant different( P〈 0.05). (3)the positive expressions 22.2 % (2/9) in lomph node meastasis were demonstrated significant different compared with PRA73.5 5% (25/34), PRB 58. 8% (20/34) in ESS( P〈0.05; P〈0.05), (4) in PRA and PRB positive cases, the living without sarcoma were demonstrated significant different compared with the death decause of sarcoma (P〈0. 01% ). Conclusion:The losing of PRA and PRB is related with increasing of their malignant degree;it is also related with their invasion and metastasis. In the lymph node, PRA and PRB is expressed positive. Prognosis is better in the cases with PRA and PRB positive than that with PRA and PRB negative.
出处 《中国临床医学》 北大核心 2007年第5期702-704,共3页 Chinese Journal of Clinical Medicine
关键词 子宫内膜间质肉瘤 孕激素受体亚型 免疫组化 Endometrial stromal sarcoma Progesterone receptor subtype Immunohistochemical
  • 相关文献

参考文献9

  • 1曹泽毅.中华妇产科学[M].北京:人民卫生出版社,2004.2170-2172.
  • 2范剑虹,吴霞,何陈云.中晚期宫颈癌的同步放化疗[J].中国临床医学,2006,13(6):983-984. 被引量:17
  • 3Horwitz KB,Tung L. Tati moto GS. Novel. mechanisms of anti progestin action[J ]. Acts Oncol, 1996,35 : 129-140.
  • 4Amett-Mansfield RL,De Fazio A,Wain GV, et al. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium[J]. Cancer Res, 2001,61: 4576- 4582.
  • 5陆叶,廖秦平,陈春玲,于丽.孕激素受体B亚型在子宫内膜癌细胞中的功能[J].北京大学学报(医学版),2006,38(5):475-479. 被引量:2
  • 6廖秦平,郑虹.孕激素受体A和B亚型在子宫内膜癌中的临床意义[J].北京大学学报(医学版),2004,36(6):616-619. 被引量:4
  • 7Mcgowan EM, Clarke CL. Effect of over expression of progesterone receptor A on endogenous progestin-senstive endpoints in breast cancer cells. Mol Endocrinol, 1999, 13: 1657-1671.
  • 8Dai DH,Kumar NS,Wolf DM,et al. Molecular tools to reestablish progestin control of endometrial cancer cell proliferation[J]. Am J Obstet Gynecol, 2001,184 : 790-797.
  • 9Smid-koopman E, Blok LJ, Kuhne LC, et al Distinct functional differences of human progesterone receptor A and B on gene expression and growth regulation in two endometrial carcinoma cell lines[J]. J Soc Gynecol Investing,2003,10: 49-157.

二级参考文献25

  • 1柯晓慧,孙杭临.晚期宫颈癌同步放化疗的疗效观察[J].江西医药,2004,39(6):413-414. 被引量:2
  • 2陆叶,于丽,陈春玲,廖秦平.雌、孕激素和米非司酮对子宫内膜癌细胞的作用[J].北京大学学报(医学版),2005,37(3):284-286. 被引量:9
  • 3Martin L, Das RM, Finn CA, et al. The inhibition by progesterone of uterine epithelial proliferation in the mouse [ J ]. J Endocrinol,1973, 57: 549 -554
  • 4Elwood M, Cole P, Rothman KJ,et al. Epidemiology of endometrial cancer[ J]. J Natl Cancer Inst, 1977, 59:1055 - 1060
  • 5Ehrlich CE, Young PC, Cleary RE. Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: Therapeutic implications[J]. Am J Obstet Gynecol, 1981,141: 539 - 546
  • 6Fukuda K, Mori M, Uchiyama M, et al. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma[J]. Gynecol Oncol, 1998 , 69:220 -225
  • 7Snijders MP, de Goeij AF, Koudstaal J, et al. Oestrogen and progesterone receptor immunocytochemistry in human hyperplastic and neoplastic endometrium[J]. J Pathol, 1992, 166: 171-177
  • 8Arnett-Mansfield RL, deFazio A, Wain GV, et al. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium[J]. Cancer Res, 2001,61: 4576 -4582
  • 9Nyholm HC, Nielsen AL, Lyndrup J, et al. Biochemical and immunohistochemical estrogen and progesterone receptors in adenomatous hyperplasia and endometrial carcinoma: correlations with stage and other clinicopathologic features [ J ]. Am J Obstet Gynecol,
  • 10Carcangiu ML, Chambers JT, Voynick IM, et al. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183patients with endometrial carcinoma. Part Ⅰ: Clinical and histologic correlations [ J ]. Am J Clin Pathol, 1990, 94:247 - 254

共引文献802

同被引文献13

  • 1马绍康,张宏图,吴令英,刘丽影,李斌.低度恶性子宫内膜间质肉瘤41例临床分析[J].中华肿瘤杂志,2007,29(1):74-78. 被引量:12
  • 2Moinfar F,Kremser ML,Man YG,et al.Allelic imbalances in endometrial stromal neoplasms:frequent genetic alterations in the nontumorous normal-appearing endometrial and myometrial tissues[J].Gynecol Oncol,2004,95(3):662-671.
  • 3Matsuura Y,Yasunaga K,Kuroki H,et al.Low-grade endometrial stromal sarcoma recurring with multiple bone and lung metastases:report of a case[J].Gynecol Oncol,2004,92(3):995-998.
  • 4Larson B,Silfversw(a)rd C,Nilsson B,et al.Endometrial stromal sarcoma of the uterus.A clinical and histopathological study.The Radiumhemmet series 1936-1981[J].Eur J Obstet Gynecol Reprod Biol,1990,35(2-3):239-249.
  • 5Reich O,Regauer S.Endometrial stromal sarcoma--observational evidence of a genetic background[J].Eur J Gynaecol Oncol,2005,26(3):288-290.
  • 6Patsner B,Mann WJ.Use of serum CA-125 in monitoring patients with uterine sarcoma.A preliminary report[J].Cancer,1988,62(7):1355-1358.
  • 7Berchuck A,Rubin SC,Hoskins WJ,et al.Treatment of endometrial stromal tumors[J].Gynecol Oncol,1990,36(1):60-65.
  • 8Maluf FC,Sabbatini P,Schwartz L,et al.Endometrial stromal sarcoma:objective response to letrozole[J].Gynecol Oncol,2001,82(2):384-388.
  • 9Pink D,Lindner T,Mrozek A,et al.Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma:single center experience with 10 cases and review of the literature[J].Gynecol Oncol,2006,101(3):464-469.
  • 10Norris HJ,Taylor HB.Mesenchymal tumors of the uterus.I.A clinical and pathological study of 53 endometrial stromal tumors[J].Cancer,1966,19(6):755-766.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部